Drug Profile
KAND 567
Alternative Names: AZD-8797; KAN-0440567; KAND-567Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Kancera
- Class 2 ring heterocyclic compounds; Amines; Analgesics; Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Neuroprotectants; Organic sulfur compounds; Pyrimidines; Small molecules; Thiazoles
- Mechanism of Action Chemokine CXCL13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myocardial infarction; SARS-CoV-2 acute respiratory disease
- Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Preclinical Spinal cord injuries
- No development reported Autoimmune disorders; Breast cancer; Cancer pain; Cardiovascular disorders
- Discontinued Multiple myeloma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Myocardial-infarction in Finland (PO, Capsule)
- 06 Feb 2024 Adverse events, efficacy and pharmacodynamics data from the phase-IIa FRACTAL study in Myocardial infarction released by Kancera ,
- 06 Feb 2024 Kancera plans a registrational phase-IIb/III trial for Cardiovascular diseases